Illumina ($ILMN), AbbVie ($ABBV), Gold ($GLD)

COMPANIES TO WATCH

Illumina ($ILMN) ◾ Biotech

Brief:

Since peaking in July, the stock has fallen 25%. In July, Illumina lowered guidance for the year and expects revenue growth of 6% compared with its previous guidance of 13-14%. They blame slowing revenue on problems with its population genomics initiatives, weakness in the direct-to-consumer market, and lower sales associated with its non-high-throughput sequencing systems.

Read More